Document Detail

Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs: an open, uncontrolled pilot study.
MedLine Citation:
PMID:  12102474     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: In 1996 we found by serendipity that 2 patients with rheumatoid arthritis (RA) who were taking clarithromycin (CM) to eradicate Helicobacter pylori experienced a regression of their RA symptoms. Following this observation, we tested the hypothesis that this reduction in symptoms could have been caused by CM administration. METHODS: We performed a 6-month, open, uncontrolled pilot study on 18 patients (14 females and 4 males, mean age 62 yrs.) with RA who had previously received DMARDs (mean 2.6) and discontinued the treatment at least one month earlier because lack of efficacy or severe side effects. Patients were treated with CM at the dose of 500 mg twice per day for the first 10 days, followed by a daily maintenance dose of 250 mg twice per day. RESULTS: 4/18 patients did not complete the treatment, 2/18 were not responsive to the treatment and 2/18 discontinued the treatment. Following ACR criteria the improvement was: 10 patients ACR 20; 6 patients ACR 50; and 2 patients ACR 70. The remaining 4 patients did not reach ACR 20 since either the number of tender or swollen joints was not to the level required. Reductions in PGE2 and soluble phospholipase A2 plasma levels were closely related to CM plasma levels. CONCLUSIONS: Ourfindings suggest that CM treatment can be beneficial in those patients who are not responsive to or cannot tolerate DMARDs. No definitive conclusions can be drawn based on the present study, due to the small sample size involved.
G Saviola; L Abdi Ali; P Rossini; L Campostrini; A Coppini; M Gori; A Ianaro; M Bucci; G de Nucci; G Cirino
Related Documents :
17264974 - Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease ...
24093314 - Endovascular aortic aneurysm repair in patients with hostile neck anatomy.
23022744 - Updated standardized endpoint definitions for transcatheter aortic valve implantation: ...
24588314 - Short-term effects of intravitreal bevacizumab on cornea and anterior chamber.
24285964 - The response of carotid intima-media thickness to medical treatment is correlated with ...
23102534 - Use of 2-hour creatinine clearance to guide cessation of continuous renal replacement t...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  20     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2002 May-Jun
Date Detail:
Created Date:  2002-07-09     Completed Date:  2003-01-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  373-8     Citation Subset:  IM    
Fondazione Salvatore Maugeri IRCCS, Rheumatology Unit, Castel Goffredo, Mantua, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Bacterial Agents / administration & dosage*
Antirheumatic Agents / adverse effects
Arthritis, Rheumatoid / drug therapy*
Clarithromycin / administration & dosage*
Dinoprostone / blood
Patient Dropouts
Phospholipases A / blood
Phospholipases A2
Pilot Projects
Treatment Outcome
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Antirheumatic Agents; 363-24-6/Dinoprostone; 81103-11-9/Clarithromycin; EC 3.1.1.-/Phospholipases A; EC A2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis s...
Next Document:  Cyclooxygenase-2 inhibition lacks immunomodulatory effects on T cells.